(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein signal transduction pathways within melanoma cells or in the endothelial cells constituting the necessary angiogenic support for tumor growth. The great promise of these therapies and their cellular targets constitutes the basis for Melanoma: Biologically Targeted Therapeutics. THE CLINlCAL PROBLEM More than four million people will be diagnosed with melanoma in the first decade of the 21st century. Half of those who will die will be individuals who would otherwise have had a life expectancy of another 25 years or more. These individuals will die of systemic systernic metastases, which are present at the time of primary surgery. Despite use of sunscreens, incidence continues to increase in developed countries worldwide. To reduce mortality, there must continue to be a focus on prevention and earlier detection through public education. Early interventions are always preferable to treatment of disseminated metastatic disease.
Contents:
Part I. Perspective on the Clinical Disease
Management of Primary Malignant Melanoma
Philip L. Bailin, Jon S. Meine, and Christine Poblete-Lopez
A Pathologist's Perspective on Prognostic Features of Malignant Melanoma
Ralph J. Tuthill
Clinical Prognostic Factors and Staging
Hamed Daw and Thomas Olencki
Part II. Biological and Targeted Therapeutics
Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression
Peter A. Cohen, Suyu Shu, and James H. Finke
Immunotherapy of Advanced Melanoma Directed at Specific Antigens
Stanley P. L. Leong and Suyu Shu
Melanoma Antigens: Vaccines and Monoclonal Antibodies
Paul B. Chapman and Jedd D. Wolchok
Interleukin-2
James W. Mier and Michael B. Atkins
Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma
Ronald M. Bukowski and Charles Tannenbaum
Interferons: Preclinical and Clinical Studies in Melanoma
Ernest C. Borden
Biochemotherapy of Melanoma
Lawrence E. Flaherty and Philip Agop Philip
Signal Transduction Abnormalities as Therapeutic Targets
Ruth Halaban and Maria C. von Willebrand
Tumor Angiogenesis
Bela Anand-Apte and Paul L. Fox
Antiangiogenic Therapy for Melanoma
Vann P. Parker
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: August, 2012
Pages: 389
Weight: 606g
Availability: Available
Subcategories: Oncology
From the same series
